NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?

Should staging and treatment decisions be made based on imaging alone?

Are you more inclined to use neoadjuvant endocrine therapy over neoadjuvant chemotherapy or upfront surgery for your ER+HER2- breast cancer patients during the COVID19 pandemic?

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...

1 Answer available

How would differing breast cancer receptors between biopsy and surgery affect your treatment recommendations?

For example, if you had a triple positive breast cancer found on breast biopsy and repeat ER/PR/HER2 testing at the time of surgical resection showed ...

1 Answer available

Would you offer trastuzumab + pertuzumab alone for patients with early stage, HER2+ breast cancer for whom TCHP is clearly indicated but who adamantly refuse any cytotoxic therapy?

3 Answers available

Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?

If so, how long is too long to wait?

1 Answer available

How should our selection for neoadjuvant chemotherapy for breast cancer change in light of COVID-19?

2 Answers available

In which group of patients you would send for RNAseq for translocations/fusions that might be missed by NGS in advanced NSCLC?

4 Answers available

In very rapidly progressive/poorly differentiated hepatocellular cancer, would you use the targeted options (sorafenib/lenvatinib) or would you try a traditional cytotoxic regimen?

1 Answer available

Would you consider chemo-radiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?

4 Answers available

How would you incorporate ctDNA to follow up a patient status post surgical resection of the primary colon adenocarcinoma and omental deposits after 6 months of FOLFOX?

Would you continue to trend ctDNA to detect early recurrence?

1 Answer available

How long after lumpectomy for DCIS in a premenopausal patient can tamoxifen be started and still retain the benefit?

This patient is interested in conceiving and therefore would like to wait to start the tamoxifen.

1 Answer available

How long do you give maintenance pemetrexed/pembrolizumab in metastatic NSCLC treated with upfront chemoimmunotherapy?

Do you ever consider stopping if stable disease and good tolerance?

3 Answers available

Would you re-introduce bisphosphonate or denosumab in a bone-only metastatic ER+ breast cancer patient with history of ONJ?

2 Answers available

Does the use of slow release hormone replacement therapy impact your adjuvant treatment recommendations for a perimenopausal patient with an intermediate Oncotype score?

For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?

1 Answer available

Does mucinous histology impact your recommendations for neoadjuvant therapy in a postmenopausal patient with HR+ HER2- breast cancer with multiple positive lymph nodes?

Being that this is a favorable histology would you use Oncotype Dx to help decide on neoadjuvant chemotherapy? Would you recommend neoadjuvant endocri...

1 Answer available

Is there evidence to support the use of definitive CRT in patients with NSCLC in separate ipsilateral lobes and mediastinal lymph node involvement?

Most trials establishing CRT as standard of care for IIIB NSCLC excluded patients with separate ipsilateral lung nodules given that they were categori...

2 Answers available

How would you approach a patient with a new axillary skin lesion with pathology suspecting a metastatic breast cancer, and no other sites of disease noted on PET imaging?

Would you treat this differently than someone who only presents with axillary nodal disease?

1 Answer available

What neoadjuvant strategies do you utilize for initially unresectable biliary tract cancer?

In your experience, what approach has been successful to bridge to surgery?

2 Answers available

When would you consider gemcitabine/cisplatin with Y90 for patients with unresectable intrahepatic cholangiocarcinoma ?

1 Answer available

How do you approach treatment for solitary fibrous tumor with a multifocal pleural-based metastatic recurrence that is surgically inoperable in a patient with good performance status?

How, if any, do you utilize genomic testing to guide systemic therapy?

2 Answers available

How would you approach a patient with metastatic squamous NSCLC that progressed on carbo/paclitaxel/pembro and has a FGFR3 S249C mutation?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

1 Answer available

Would you offer additional therapy for a patient with HR+ breast cancer on AI+OS who is found to have a focus of ovarian metastasis at the time of elective BSO?

Additionally, would the finding of any mutations, such as ESR1, change your recommendation?

2 Answers available

What is your strategy for ovarian suppression if unable to achieve goal estradiol levels with leuprolide 3.75mg monthly dose?

Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...

2 Answers available

Do you recommend ovarian suppression in all premenopausal women under age 35 with ER positive breast cancer based on the SOFT/TEXT data, regardless of other risk features?

For example, is this still your approach in women with small tumors or node negative disease?

2 Answers available

Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

If so, for what platelet count threshold and do you have a preference as to which agent?

1 Answer available

What is the role for adjuvant chemotherapy and/or radiation in ampullary carcinoma?

Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...

1 Answer available

How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?

1 Answer available

Is tamoxifen absolutely contraindicated in pre-menopausal women with Lynch syndrome?

2 Answers available

How do you treat a fit patient with a solitary pulmonary nodule (2cm) which is biopsy-proven small cell lung carcinoma?

PET-CT and Brain MRI are negative for other evidence of disease.

2 Answers available

Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?

Would nivo + Ipi be appropriate in this situation, especially if high TMB?

4 Answers available

What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?

Especially in light of the new Guardant data presented at AACR 2019

2 Answers available

How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

3 Answers available

How do you advise women who are at high risk for breast cancer and for whom annual screening breast MRIs are recommended regarding the long-term risks of gadolinium contrast?

1 Answer available

How do you proceed if a breast cancer patient has imaging concerning for pulmonary lymphangitic carcinomatosis but no other evidence of metastatic disease?

1 Answer available

How would you approach metastatic adenocarcinoma of the lung with ROS1 rearrangement by FISH and EGFR L858R mutation by NGS?

2 Answers available

Would you offer contralateral prophylactic mastectomy in an older BRCA1 + woman who is getting treated for newly diagnosed BC with mastectomy and SLNB?

Knowing that benefit of contralateral mastectomy is lower in older women who has already manifested BRCA related cancer and 10-20 % mastectomy related...

1 Answer available

How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?

What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?

1 Answer available

How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

2 Answers available

What is your approach to oligometastatic HER2 positive breast cancer, particularly after excellent clinical response in all sites of disease to trastuzumab, pertuzumab, and a taxane?

2 Answers available

How would you treat a metastatic lung adenocarcinoma with MET exon 14 skip mutation on ctDNA, negative tissue NGS and PD-L1 of >50%?

The NCCN guidelines regard MET exon 14 skip mutation as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

1 Answer available

What is your preferred induction chemotherapy for stage IIIA NSCLC squamous and adenocarcinoma?

Is there any advantage of one regimen over the others?

1 Answer available

How would you manage a postmenopausal female with a history of early stage invasive ductal ER+/HER2- breast cancer s/p mastectomy who has a local recurrence of ER+/Her2 - lobular carcinoma while on letrozole?

2 Answers available

Do you skip sentinel lymph node biopsy for women >70 years old with small (< 2cm) HR+ node-negative breast cancer?

Is this new SSO choosing widely guideline being widely adopted and are there any concerns regarding this for clinical practice?

1 Answer available

Would you finish neoadjuvant TC in a postmenopausal stage I TNBC patient who transferred care to your practice after 1 cycle or would you proceed with surgery and finish chemo adjuvantly?

If finished adjuvantly, what would you do -- continue TC or change chemotherapy?

1 Answer available

Should neoadjuvant chemotherapy be recommended for HER2+, clinically LN- breast cancer measuring 2-3cm?

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

2 Answers available

How would you approach adjuvant chemotherapy and radiation options in a patient with locally advanced TNBC and Diamond-Blackfan Anemia s/p lumpectomy?

Given that DBA is associated with increased incidence of MDS, AML and other solid tumors, would this modify your treatment recommendations?

1 Answer available

How would you manage a patient with newly diagnosed synchronous triple positive and metaplastic triple negative breast cancers?

For early stage disease in a single breast, would you consider neoadjuvant chemotherapy or upfront surgical staging followed by adjuvant therapy? What...

2 Answers available

How would you approach a patient with Stage III EGFR+ NSCLC who develops oligometastatic disease while on consolidation durvalumab?

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

1 Answer available

Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?

If so, what is your approach to sequencing and timing of targeted therapy and local therapy?

1 Answer available

How would you manage a patient with synchronous breast and ovarian cancer, s/p neoadjuvant chemotherapy and surgery for ER+/HER2- breast cancer and found to have an ER+ ovarian cancer nodal metastases at TAH/BSO?

RP node with treatment related changes and surgical specimen from TAH/BSO no other foci of malignancy found.

1 Answer available

How long do you give neoadjuvant therapy in resectable/borderline resectable pancreatic cancer, when you are considering chemoradiotherapy as part of your neoadjuvant strategy?

I have seen anywhere from 4-6 months utilized. Is there any data to guide your strategy?

1 Answer available

Will you consider additional capecitabine in a patient with TNBC, residual disease after neo-adjuvant chemo, before getting adjuvant pembrolizumab or placebo on SWOG 1418 clinical trial?

3 Answers available

In light of recent data from ASCO 2019 and the NEJM, would you recommend induction chemotherapy or an adjuvant approach in combination with chemoradiation for locally advanced nasopharyngeal carcinoma?

Does your approach differ by EBV status?

1 Answer available

What systemic therapy would you offer a postmenopausal women with oligometastatic sternal disease which developed while on tamoxifen?

Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...

1 Answer available

Do you consider neoadjuvant pertuzumab for node negative multifocal HER2+/ER+ IDC without any single focus >2 cm?

2 Answers available

Do you recommend switching from chemotherapy to AI+CDK4/6 inhibitor after resolution of visceral crisis in a patient with HR+, HER2- metastatic breast cancer?

If so, after how many cycles of chemotherapy would you switch?

5 Answers available

Do you offer neoadjuvant therapy to a postmenopausal cT1cN0 , HER2+, ER/PR+ breast IDC or recommend surgery first?

4 Answers available

In what circumstances, if any, do you administer concurrent capecitabine with radiation therapy in the treatment of breast cancer?

1 Answer available

Do you consider omitting adjuvant radiation therapy in an older patient with node positive TNBC who achieve pCR to neoadjuvant chemotherapy?

2 Answers available

How do you manage patients with HER2 positive breast cancer who have progressive CNS metastases after prior exposure to pertuzumab, trastuzumab, TDM1, and lapatinib?

1 Answer available

Do you give systemic therapy for triple negative breast cancer with brain metastasis and no other sites of disease?

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?

4 Answers available

Should breast cancer patients with never-treated latent TB and for whom chemotherapy is indicated be treated for latent TB during chemotherapy?

2 Answers available

How do you treat patients with metastatic ER+HER2- breast cancer with activating PI3K mutations after progression on everolimus?

2 Answers available

Would you consider giving tamoxifen prophylaxis to young women with pathogenic BRCA2 muations who are <35 years old?

Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.

1 Answer available

What systemic therapy would you offer to a postmenopausal patient with an unresectable local recurrence of HER2+/ER weakly + IDC?

In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about ...

1 Answer available

For patients with EGFR-mutant NSCLC who progress on osimertinib, do you repeat tumor molecular profiling?

If so do you favor repeat tumor biopsy or cfDNA?

2 Answers available

What is the most appropriate adjuvant chemotherpay regimen for pre-menopausal, pT1bN0, TNBC?

Would you forego anthracycline?

1 Answer available

Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial. https://www.ncbi.nlm.nih.go...

3 Answers available

For ER+ breast cancers that are clinical Stage IIB (T2N1) nearing locally advanced stages, what criteria do you use to determine if you would offer neoadjuvant chemotherapy?

3 Answers available

Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?

1 Answer available

What would be your next line of therapy for a postmenopausal metastatic ER+/Her 2- BC, s/p anastrazole and palbociclib/fulvestrant who has progressive disease and ESR1 mutation on ctDNA?

2 Answers available

After partial mastectomy, would you consider Oncotype for an older male with HR +/Her 2- IDC, T1cN0, Grade 2 disease?

Do you see a role for adjuvant radiation therapy?

1 Answer available

What is the preferred clinical management of hyperglycemia related to alpelisib?

1 Answer available

With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?

1 Answer available

How do you approach a stage IIIC triple positive IDC, s/p neoadjuvant TCH and P, lumpectomy, and ALND with significant residual disease at the time of surgery?

Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?

3 Answers available

How would you approach a stage 1 HR+/HER2- (low clinical risk) pre-menopausal patient (<50 y.o) with Oncotype DX RS of 24?

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

2 Answers available

If a patient on ovarian suppression with goserelin for ER+HER2- BC achieves post-menopausal-range estradiol levels but does not achieve post-menopausal FSH levels, is she suppressed?

Patient has hot flashes.

2 Answers available

In light of recent data suggesting limited activity of Atezolizumab monotherapy in the 2nd line treatment of ES-SCLC, would you still offer Atezolizumab maintenance following combination chemo-IO in the first line setting?

1 Answer available

Based on new data from ASCO2019, would you consider gefitinib +chemotherapy instead of osimertinib frontline for EGFRm metastatic NSCLC pts?

http://abstracts.asco.org/239/AbstView_239_262655.html

5 Answers available

Would you extrapolate data from PACIFIC trial for unresectable disease to consider consolidation therapy with durvalumab for Stage III NSCLC with single-station N2 disease amenable to lobectomy?

4 Answers available

How would you manage a locally advanced TNBC and a malignant appearing renal mass suspicious for a synchronous renal cell carcinoma?

1 Answer available

In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

If so, would you combine them vs monotherapy? Patient ECOG is 1

1 Answer available

In which patients with stage 1 triple negative breast cancer would you utilize neoadjuvant chemotherapy?

Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?

4 Answers available

Would you preform Mammaprint to determine whether or not to offer neoadjuvant chemotherapy to a high risk ER+ breast cancer?

1 Answer available

Would you offer adjuvant chemotherapy in a patient with extensive LCIS/DCIS s/p mastectomy and multiple positive lymph nodes due to surgical seeding?

If so, would you treat as node + BC with anthracycline and taxane regimen or non-anthracycline regimen (i.e docetaxel and cyc...

1 Answer available

When do you consider total neoadjuvant therapy (chemotherapy and chemoradiation) for rectal cancer?

1 Answer available

How do you advise patients looking for 2nd opinions while on standard-of-care, first line treatment for metastatic ER+HER2- BC(i.e. a CDK4/6 inhibitor + aromatase inhibitor) to bolster requests for chemotherapy when non indicated?

1 Answer available

How would you treat a patient with metastatic NSCLC on pembrolizumab with a sustained complete response, now with 2 isolated small liver lesions?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

1 Answer available

How would your treat a pregnant woman (2nd trimester) with multifocal HER2+ ER- early stage breast cancer?

greatest measuring 1.0cm.

1 Answer available

Would you give additional chemotherapy to women with stage III HER2+ breast cancer who have a grossly suboptimal response to neoadjuvant TCHP x6?

Or would you proceed with standard-of-care adjuvant approach for high risk patients?

1 Answer available

Do you continue ovarian suppression for pre-menopausal women with HR+ breast cancer after progression on ovarian suppression + AI + CDK4/6 inhibitor (i.e. when fulvestrant is the appropriate next line of therapy)?

1 Answer available

When would you consider neratinib in a patient with locally advanced HR positive, Her2 positive breast cancer who received one year of trastuzumab and pertuzumab?

1 Answer available

Which patients with metastatic breast cancer should have mastectomy?

1 Answer available

What chemotherapy regimen would you recommend for high risk ER+/Her2- LN negative breast cancer with high genomic risk disease?

I.e. according to Mammaprint test?

1 Answer available

After progression on osimertinib, do you recommend overlapping TKI with 2nd line chemotherapy to avoid accelerated disease progression?

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

1 Answer available

With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%?

1 Answer available

How would you manage an elderly patient with a history of stage I CLL and newly diagnosed metastatic ER+/HER2+ breast cancer?

1 Answer available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

1 Answer available

How would you treat frontline metastatic ER+HER2- breast cancer with activating PI3K mutations?

1 Answer available

Should GnRH agonist therapy be continued beyond 5 years (along with an aromatase inhibitor) in young pre-menopausal women with high risk breast cancer who continue to have ovarian function at 5 years of endocrine treatment?

1 Answer available

How would you manage DCIS diagnosed in the first trimester of pregnancy?

1 Answer available

Would you perform an oncotype DX in a patient with a 0.5cm ER positive breast cancer with one lymph node positive for macrometastatic disease?

2 Answers available

What would you use as next line of treatment for a patient with ROS1 positive metastatic NSCLC progressing on crizotinib?

Would you use Lorlatinib , chemotherapy, immunotherapy or Chemo- immunonotherapy?

1 Answer available

How do you manage a newly diagnosed locally advanced ER+/HER2- breast cancer with synchronous diagnosis of metastatic melanoma?

1 Answer available

How do you manage a patient with newly diagnosed stage IIA triple negative breast cancer with a history of renal transplantation on immunosuppressive therapy?

1 Answer available

What is the preferred treatment approach for patients with metastatic phyllodes tumor?

1 Answer available

How will the findings from the study of adjuvant capecitabine in TNBC presented at SABCS 2018 (CIBOMA/2004-01_GEICAM/2003-11) affect standard of care?

1 Answer available

What adjuvant treatment would you use in a pT1miN0M0 ER -/HER2 IDC of the breast after bilateral mastectomies?

Patient did not receive neoadjuvant therapy.

3 Answers available

How would you advise a pre-menopausal, HR-, HER2+ BC with treated brain metastases and NED while on trastuzumab/pertuzumab who wants to conceive?

1 Answer available

When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?

1 Answer available

Is post-mastectomy chest wall radiotherapy indicated for DCIS with very close (<1mm) or positive margins?

4 Answers available

Would you resume durvalumab after several month hiatus due to IO unrelated medical comorbidities that has since resolved?

If it is still within the 12 month period and no disease recurrence?

3 Answers available

When do you consider it too late after breast surgery to offer adjuvant chemotherapy to a patient with high risk non-metastatic breast cancer?

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

1 Answer available

How would you treat a pregnant woman in the third trimester with locally advanced, hormone receptor positive, HER2 positive breast cancer?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

2 Answers available

Would you consider adjuvant chemotherapy for a patient with T1a N0 triple negative breast cancer?

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

1 Answer available

How would you treat a patient with EGFR+ oligo-metastatic lung adenocarcinoma status post resection of the primary and metastatic sites?

Would you give adjuvant chemotherapy or start osimertinib?

1 Answer available

What chemotherapy regimen would you recommend to a patient with local regional recurrent ER negative, HER2 positive breast cancer who received TCH more than 5 years ago?

The CALOR trial included patients that could receive HER2-targeted therapy.

1 Answer available

What would you offer as systemic therapy to an elderly woman (age >75 years) with HR negative, HER2 positive, lymph node negative breast cancer whose tumor is 2 cm or less?

1 Answer available

Do you offer pembrolizumab monotherapy or carbo-pemetrexed-pembrolizumab to a patient with Stage IV large cell NSCLC with PD-L1 of 80% and KRAS+STK11 mutation?

Some retrospective data reports that STK11 (AKA LKB1) makes NSCLC resistant to immunotherapy.

2 Answers available

How would you approach a biopsy proven NSCLC patient with mediastinum negative disease and contralateral suspicious spiculated PET avid nodule without pathologic diagnosis?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

2 Answers available

In a premenopausal woman with low risk, early stage HR-positive breast cancer who is unable to discontinue a strong CYP2D6 inhibitor, do you use still utilize tamoxifen versus an AI with ovarian suppression?

2 Answers available

How do you manage elderly patients with borderline PS and ER+ inflammatory breast cancer without metastasis?

Would you consider neo-adjuvant chemotherapy or treat with endocrine therapy?

1 Answer available

How do you counsel your breast-cancer survivors about weight-loss/dietary modifications?

Do your recommendations differ if patients are pre or postmenopausal given the data?

3 Answers available

Should atezolizumab and nab-paclitaxel now be used in first line therapy for metastatic, triple negative breast cancer?

Have the results from IMpassion130 changed the standard of care?

2 Answers available

For patients with triple negative breast cancer who have a minimal response to neoadjuvant chemotherapy, do you do additional testing to sub-categorize the cancer and find a potential target (e.g. androgen receptor, etc)?

5 Answers available

In patients who develop a VTE on palbociclib, do you discontinue therapy or continue as long as the patient is receiving adequate anticoagulation therapy?

1 Answer available

Do you use docetaxel interchangeably with paclitaxel in breast cancer?

Does the answer vary based on whether it is neo/adjuvant or metastatic setting?

1 Answer available

What is your approach to adjuvant endocrine therapy in high-risk premenopausal women with ER/PR+ Her2+ breast cancer?

How applicable is the SOFT/TEXT data in this setting ?

4 Answers available

Do you offer adjuvant chemotherapy and/or radiotherapy for patients with resected atypical carcinoid of the lung with positive mediastinal lymph nodes (T3N2M0)?

1 Answer available

Do you routinely offer neo-adjuvant chemotherapy for patient with triple negative metaplastic breast cancer?

2 Answers available

Would you offer upfront osimertinib rather than whole brain irradiation for a patient with stage IV, EGFR exon 19 mutated lung adenocarcinoma who presents with leptomeningeal metastases?

1 Answer available

Would you offer chemotherapy to a patient with an in-breast recurrence less than 2 years after a history of lymph node positive ER+PR+HER2- breast cancer treated with mastectomy and adjuvant hormonal blockade?

1 Answer available

Would you re-challenge patients with an EGFR TKI beyond progression if repeated biopsies show redemostration of a sensitizing mutation (exon 19 deletion) and no other resistance mechanisms?

1 Answer available

What adjuvant systemic therapy do you recommend for a pre-menopausal patient with a localized recurrence of ER+PR+HER2- invasive ductal carcinoma while on adjuvant ovarian suppression with an aromatase inhibitor?

2 Answers available

What is the next step in management following surgical resection of a primary adenoid cystic carcinoma of the lung?

Would you consider radiation and/or chemotherapy?

1 Answer available

Would you consider neoadjuvant endocrine therapy instead of chemotherapy for a pre-menopausal patient with a node-positive, ER+PR+, lobular breast cancer?

Initial pathology additionally yields low Ki-67 and is HER2 negative.

1 Answer available

Is there a role for checkpoint inhibition in patients with advanced, high PD-L1 expressing, chemotherapy-refractory thymoma?

What if the patient has thymoma-associated myasthenia gravis?

2 Answers available

What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

1 Answer available

Would you send a lung cancer patient for genetic counseling/germline mutation testing if they are harboring mutations in NGS with variation allele frequency between >=50%?

Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients th...

2 Answers available

Would you offer adjuvant chemotherapy to a patient with T3N0M0 NSCLC if the reason for the T3 stage was due to multiple tumor nodules in the same lobe?

All tumors in this case were <2cm in size.

1 Answer available

When do you add an adjuvant bone-modifying agent in patients with history of localized breast cancer?

Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?

1 Answer available

Would you add HER2 targeted therapy to adjuvant chemotherapy for a patient with initial breast biopsy showing a ER/PR positive, HER2 negative invasive ductal carcinoma but mastectomy sample showing equivocal Her2 by FISH on initial assay with an alternative probe testing positive?

(HER2/CEP17 ratio <2.0, copy number >4.0 and <6.0 signals/cell)

1 Answer available

Would you consider neoadjuvant endocrine therapy in a postmenopausal patient with ER + locally advanced breast cancer with nodal disease who wants to avoid chemotherapy?

3 Answers available

How do you manage a patient with multiple similar appearing ground glass opacities (~8-9) on Chest CT where one has been surgically removed and confirmed to be adenocarcinoma in situ?

There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...

1 Answer available

What would be your next line of treatment for NSCLC adenocarcinoma that has recurred after chemoradiation with cis/etoposide?

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

1 Answer available

What is your systemic therapy approach to women with isolated local recurrences of hormone-receptor positive breast cancer?

How does the timing of recurrence play into your decision?

2 Answers available

How would you treat metastatic NSCLC in a non-smoker with bone biopsy showing adenocarcinoma of lung origin but inadequate tissue for mutational panel or PD-L1?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

2 Answers available

How would you approach the treatment of resectable NSCLC with a solitary resectable brain metastasis and no other sites of metastasis?

Would you offer adjuvant therapy post resection?

3 Answers available

Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?

In the setting of the recent TailorRx data, would these patients be considered more high risk?

1 Answer available

How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?

3 Answers available

Would you recommend 10 years instead of 5 years of tamoxifen in a premenopausal woman with early stage, node negative ER/PR/HER2 positive breast cancer?

Pt is healthy and tolerating Tamoxifen well.

1 Answer available

How would you treat a patient with a history of ER+ breast cancer over 10 years ago, now presenting with an ER+ loco-regional recurrence while still on Tamoxifen?

In a patient treated over 10 years ago with mastectomy and chemo now with recurrence in the ipislateral axilla, would you offer additional with chemot...

1 Answer available

What is your approach to adjuvant HER-2 directed therapy in a patient who developed cardiotoxicity following neoadjuvant TC-HP?

Can these patients be re-challenged with Herceptin?

6 Answers available

Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

1 Answer available

In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it consider safe to give immune checkpoint blockers?

1 Answer available

Would you use 6 months (instead of 12 months) of Herceptin for locally advanced Her-2 positive breast cancer patients?

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

3 Answers available

Do you use gene expression profiling for premenopausal women with hormone receptor positive breast cancer with 1-3 positive lymph nodes?

2 Answers available

For patients at high risk of breast cancer, do you recommend tomosynthesis over traditional two-view screening mammogram?

1 Answer available

How do you manage a locally advanced hormone receptor positive invasive ductal carcinoma with neuroendocrine (small cell) features?

If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?

1 Answer available

How do you explain the risks and benefits of palliative radiation therapy to patients with fungating breast masses?

Patients are understandably concerned about the risks and benefits of radiation to an oozing, bleeding, ulcerated breast.

2 Answers available

For pre-menopausal patients with high-risk ER+ disease, and who desire pregnancy, what is the best time frame to pause endocrine therapy to allow for pregnancy?

High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.

1 Answer available

For early-stage, HR+ Her2- breast cancers, when do you use OncotypeDx v. Mammaprint?

2 Answers available

Do you ever consider local therapy to oligometastatic hormone-receptor positive breast cancer?

3 Answers available

What is your approach to women with early-stage hormone responsive breast cancer intolerant of AI's who want to remain on endocrine therapy but have contraindications to tamoxifen?

1 Answer available

What is the role of neoadjuvant breast radiation in patients with triple negative breast cancer progressing on AC-T?

Pt clinically has inflammatory breast cancer making mastectomy a poor option.

1 Answer available

What would be your choice of endocrine therapy (if any) for a premenopausal woman with an ER positive 2nd DCIS in ipsilateral breast who has completed 5 years of tamoxifen after lumpectomy of 1st DCIS?

First episode was 10 years ago and patient did not receive XRT. Would you give XRT now?

1 Answer available

When (if ever) would you use fulvestrant up-front instead of an aromatase inhibitor for ER+ or PR+ metastatic breast cancer?

4 Answers available

What do you do for patients with HR+ inflammatory breast cancer who do not achieve a pCR with neoadjuvant chemotherapy?

Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?

2 Answers available

How do you decide to choose TC vs CMF for HER2 negative breast cancer patients who warrant adjuvant chemotherapy?

2 Answers available

How do you approach adjuvant therapy in patients who have a poor clinical response to neoadjuvant endocrine therapy?

No prior chemotherapy.

2 Answers available

How do you counsel a patient with a history of breast cancer regarding use of breast MRI for screening?

Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...

1 Answer available

How do you decide on the sequence of systemic and local therapy for patients with oligometastatic NSCLC?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

1 Answer available

What is your approach to young healthy women with locally advanced breast cancer and biopsy-proven low cervical lymph nodes?

Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...

2 Answers available

What is your adjuvant treatment approach to patients with strongly hormone-receptor positive breast cancer who have minimal response to neoadjuvant chemotherapy?

2 Answers available

Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?

These patients have been largely excluded from these trials. What if the infection is well controlled?

3 Answers available

Are mirena (progesterone-coated) IUDs contraindicated in patient with a history of hormone-receptor positive breast cancer?

1 Answer available

How would you treat a patient with a small (<0.5 cm) node negative, grade 3 BRCA1 mutated triple negative breast cancer?

An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...

2 Answers available

Do you pursue testing for ERBB2 mutations in patients with metastatic breast cancer who are clinically HER2-negative by IHC and FISH?

If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib?

1 Answer available

Do you use an alternative dosing regimen for CDK4/6 inhibitor in patient with benign ethnic leukopenia ?

Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.

1 Answer available

Do you intentionally modify your breast cancer treatment plans for those on chronic immunosuppression to avoid secondary cancers?

This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...

1 Answer available

In what circumstances would you repeat bio markers (ER, PR, HER2) in a patient with breast cancer who has residual disease after neo-adjuvant chemotherapy?

2 Answers available

Do you send Oncotype or Mammaprint as a predictive tool for patients with high grade (3/3) lymph node negative ER+ breast cancers?

What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?

1 Answer available

What regimen would you choose for patients with breast cancer requiring adjuvant chemotherapy whose livelihoods depend on fine dexterity (such as a professional musician)?

Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?

1 Answer available

Would you feel comfortable giving a HER2+ breast cancer patient her next cycle of TCHP (Taxotere + carboplatin + Herceptin + Perjeta) on day 17 of the previous cycle?

Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...

1 Answer available

What is your preferred non-taxane chemotherapy regimen for early-stage HER2 negative breast cancer patients who develop grade 3/4 neuropathy before completion of taxane-based therapy?

Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...

1 Answer available

Are Mammaprint and OncotypeDx as useful in stratifying risk in patients with early stage HR+, HER2 negative lobular carcinomas, as in those with ductal carcinomas?

1 Answer available

In the high-risk adjuvant or metastatic setting when you initiate patients on ovarian suppression with the plan to start an AI, what protocol do you follow in terms of rechecking estradiol?

How often will you monitor it? In the setting that patient is morbidly obese, does your strategy change?

2 Answers available

What factors do you consider when you are deciding whether to recommend endocrine therapy for a woman who has had a mastectomy for DCIS for contralateral breast cancer risk reduction?

1 Answer available

Would you prescribe an aromatase inhibitor prophylactically for a post-menopausal woman with a deleterious BRCA2 mutation and a history of DCIS who declines prophylactic mastectomy?

Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...

1 Answer available

Do you use endocrine therapy concurrently or sequentially with radiation therapy in hormone receptor positive breast cancer patients?

In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?

1 Answer available

Do you utilize genomic testing (oncotype, breast cancer index) in HR positive breast cancer to make recommendations regarding the duration of endocrine therapy?

Given the data noting predictive benefit of utilizing genomic testing in predicting later relapse of hormone receptor positive breast cancer.

2 Answers available

Is sentinel lymph node biopsy several weeks after partial mastectomy as reliable as sentinel lymph node biopsy done at the time of partial mastectomy?

2 Answers available

Would you consider localized therapies such as radiofrequency ablation to a lung metastasis or Yttrium-90 for liver metastases for disease control for ER+HER2- breast cancer patients with visceral oligometastatic disease who have progressed on all hormonally-targeted therapies and have chemotherapy as their next standard-of-care systemic treatment option?

1 Answer available

Would you consider exemestane (instead of fulvestrant) in post-menopausal patients with hormone receptor pos, HER2- breast cancer who progress on letrozole or anastrozole?

There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...

1 Answer available

Knowing that spread of lobular carcinoma is often more insidious than ductal carcinoma, do you order different staging studies for lobular cancer?

For example, would you order a PET/CT to evaluate for lymphatic or distant metastatic disease?

1 Answer available

How do you handle hormonal therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

1 Answer available

Should additional molecular testing be performed on triple negative breast cancers up-front to identify potentially targetable mutations (e.g. activating HER2 mutations, homologous recombination repair deficiency assays, etc)?

Does your institution do this routinely?

1 Answer available

In women in whom you suspect chemotherapy-induced amenorrhea and are required to start an AI, what is your strategy with regard to ovarian suppression?

I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?

1 Answer available

Based on the findings of the CALOR trial, among which group of patients with locoregional recurrence of hormone-receptor positive breast cancer would you treat with chemotherapy?

Do you prefer doing this through a "neoadjuvant" approach vs. post-operatively? CALOR trial

1 Answer available

In which patients will you consider the use of adjuvant pertuzumab for HER2 positive early stage breast cancer?

How does the modest results of the APHINITY trial impact your practice?

1 Answer available

Is there a preferential approach for systemic therapy for triple negative breast cancer patients with leptomeningeal disease?

Aside from local therapies (intrathecal, radiation), are there therapies that are known to have better CNS penetration?

1 Answer available

When do you suggest ovarian suppression for fertility preservation in premenopausal women receiving neo/adjuvant chemotherapy?

Do you reserve this approach for only women with triple negative breast cancer or all-comers?

1 Answer available

Do you rely on Ki67 as an estimate of proliferation to guide the decision for chemotherapy in premenopausal women with hormonally-driven breast tumors?

Is this in addition to or mutually exclusive from oncotype/mammaprint?

1 Answer available

What is the upper limits of anthracycline dose you are willing to give in a treatment-refractory metastatic breast cancer patient if the patient is responding to salvage weekly adriamycin after progression on multiple prior regimens?

Patient has hormone-refracatory disease, had high visceral burden (pulmonary mets, bone, lymph). Progressed on taxane, xeloda, gemcitabine. Now ...

1 Answer available

How do you treat HER2-equivocal breast cancer in the neoadjuvant setting?

What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?

1 Answer available

Do you have a certain size threshold below which you change chemotherapy recommendations for a small, triple negative breast cancer?

(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...

2 Answers available

In which patients would you recommend extending adjuvant AI-based therapy beyond 5 years?

2 Answers available

Will you continue anti-estrogen therapy in the setting of initiation of TDM-1 for patients with metastatic ER+/HER2+ breast cancer?

1 Answer available

How does genomic profiling/next-generation sequencing assays influence your treatment recommendations in metastatic breast cancer?

At what point do you send these test, and in what instances do the results influence your treatment recommendations?

1 Answer available

At what point do you prescribe duloxetine for the treatment of AIMS (aromatase inhibitor induced musculoskeletal syndrome)?

2 Answers available

What is the role of platinum agents in the treatment of metastatic breast cancer in patients with BRCA mutations?

2 Answers available

How would you approach the management of a patient with oligometastatic NSCLC characterized by a LUL mass and a solitary adrenal metastasis, assuming a good performance status?

1 Answer available

Would you recommend the SOFT/TEXT adjuvant approach of ovarian suppression/AI in a premenopausal woman with high-risk disease who still desires to have a pregnancy?

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2013-03-15

Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ.

International journal of radiation oncology, biology, physics, 2011-05-01

Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?

International journal of radiation oncology, biology, physics, 2011-11-01

Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

The New England journal of medicine, 2015-03-05

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N. Engl. J. Med., 2015-01-29

Adjuvant ovarian suppression in premenopausal breast cancer.

Lancet, 2007-05-19

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

The Lancet. Oncology, 2016-12

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Nat. Med.,

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Clinical breast cancer, 2006-12

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.

Lancet (London, England), 2009-12-19

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

The Lancet. Oncology, 2014-06

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2012-11-08

Trastuzumab emtansine for HER2-positive advanced breast cancer.

J. Clin. Oncol.,

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

J. Clin. Oncol., 2019 Oct 16

Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor–Positive Breast Cancer

N. Engl. J. Med., 2017-07-13

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04

Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities.

Am J Case Rep, 2017-02-28

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.

The New England journal of medicine, 2016-08-25

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Lancet, 2017-09-09

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.

Oncologist, 2007-09-01

How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.

Journal of the National Cancer Institute, 2006-12-20

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.

Medicine and science in sports and exercise, 2010-07

American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.

J Clin Oncol, 2016 Feb 20

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Curr Breast Cancer Rep, 2016-01-01

Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise.

Crit Rev Food Sci Nutr, 2018 Apr 19

Meat, eggs, full-fat dairy, and nutritional boogeymen: Does the way in which animals are raised affect health differently in humans?

JAMA, 2018-02-20

Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.

JAMA Oncol,

Prolonged Nightly Fasting and Breast Cancer Prognosis.

The New England journal of medicine, 2012-08-02

Combination anastrozole and fulvestrant in metastatic breast cancer.

Lancet (London, England), 2016-12-17

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Breast cancer research and treatment, 2012-11

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

British journal of clinical pharmacology, 2016-06

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

The New England journal of medicine, 2014-07-10

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Fertility and sterility, 2016-03

Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all.

Breast Cancer, 2017-09-01

Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.

Journal of the National Cancer Institute, 2010-07-07

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

J Natl Cancer Inst, 2006 Jul 5

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

J. Natl. Cancer Inst., 2010-07-07

Tamoxifen and the factor V Leiden mutation.

J. Clin. Oncol., 2003-10-01

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.

Lancet (London, England), 2013-03-09

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-20

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

Journal of the National Cancer Institute, 2013-07-17

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

The New England journal of medicine, 2016-07-21

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Breast Cancer Res. Treat., 2005-01-01

The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology.

Breast, 2016-12-01

Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision.

Zhonghua Zhong Liu Za Zhi, 2016-07-01

[Feasibility analysis of sentinel lymph node biopsy in patients with breast cancer after local lumpectomy].

Breast, 2016-08-01

Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Cancer, 2010-11-15

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

The breast journal, 2017-11

An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.

The New England journal of medicine, 2011-06-23

Exemestane for breast-cancer prevention in postmenopausal women.

Lancet (London, England), 2016-02-27

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Cancer investigation, 2011-11

The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Cancer Treat. Rev., 2011-10-01

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Ann. Oncol., 2013-12-01

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Nat Rev Clin Oncol, 2016-08-01

Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

The Lancet. Oncology, 2018-02

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

Ann. Oncol.,

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.

Clin. Cancer Res., 2018 Mar 26

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.

Ann. Oncol.,

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

Breast Cancer, 2012 Apr 25

Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.

Annals of surgical oncology, 2018-10

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

Cancer, 2004-10-15

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Lancet Oncol., 2016 Jun 23

Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.

BMJ, 2016 Sep 30

Revisiting the drug interaction between tamoxifen and SSRI antidepressants.

The New England journal of medicine, 2018-07-12

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Journal of the National Cancer Institute, 2017-02

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.

N Engl J Med, 2015 Jan 8

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

The Lancet. Oncology, 2012-07

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

Annu. Rev. Med., 2015 Aug 28

Adjuvant Bisphosphonates and Breast Cancer Survival.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

The New England journal of medicine, 2018-07-12

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Cancer, 2006-09-15

Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.

Cancer Discov,

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Clin. Cancer Res.,

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with

N. Engl. J. Med.,

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

The Lancet. Oncology, 2019-01

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology, 2017-12

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

J Thorac Oncol, 2016 Jul

Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe.

Eur. J. Cancer, 2017 Aug 04

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.

J Thorac Oncol, 2018 Feb

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.

J. Clin. Oncol., 2018 Jun 15

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

The Lancet. Oncology, 2015-02

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

J. Clin. Oncol., 2017 Dec 14

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

NPJ breast cancer, 2017

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

N Engl J Med, 2018 Oct 20

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

The Lancet. Respiratory medicine, 2017-11

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Ann. Thorac. Surg.,

Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina.

Annals of surgical oncology, 2009-06

Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.

Annals of surgical oncology, 2017-02

Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.

Breast Cancer Res. Treat., 2017 Sep 15

Characteristics and prognosis of breast cancer after liver or kidney transplantation.

JAMA, 2011-11-02

Spectrum of cancer risk among US solid organ transplant recipients.

The New England journal of medicine, 2016-11-17

Palbociclib and Letrozole in Advanced Breast Cancer.

The Lancet. Oncology, 2016-04

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Breast cancer research : BCR, 2016-06-28

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Annals of surgical oncology, 2011-01

Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up.

J Clin Oncol, 2011 Jan 10

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-07-20

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

JAMA Oncol,

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

N Engl J Med, 2014 Sep 27

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-09-15

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

J. Clin. Oncol., 2018 Mar 29

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

JAMA Oncol,

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

J. Clin. Oncol., 2020 Feb 20

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?

The Lancet. Oncology, 2013-10

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04

What threshold for adjuvant therapy in older breast cancer patients?

N Engl J Med, 2011 Oct 6

Adjuvant trastuzumab in HER2-positive breast cancer.

Lancet Oncol., 2012-01-01

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

JAMA oncology, 2017-05-01

Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.

J. Clin. Oncol., 2017 Oct 02

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

The New England journal of medicine, 2015-02-19

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Breast Cancer Res Treat, 2009 Jun

Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.

JAMA, 2012 Jul 11

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

Radiation oncology (London, England), 2011-09-28

Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

JAMA surgery, 2019-05-29

Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.

J. Clin. Oncol., 2020 Feb 27

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Trials, 2013 Aug 19

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

Ann. Oncol., 2012 Jun 06

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

Cancer,

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Clin Transl Oncol, 2018 Mar 28

Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.

N. Engl. J. Med., 2017 Jun 04

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.

The New England journal of medicine, 2019-06-20

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

The New England journal of medicine, 2018-01-11

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

N. Engl. J. Med., 2019 May 31

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.

The New England journal of medicine, 2018-12-06

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

J Thorac Oncol, 2019 Jan 18

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.

The New England journal of medicine, 2019-02-14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N. Engl. J. Med.,

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

The New England journal of medicine, 2012-02-09

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Cancer control : journal of the Moffitt Cancer Center, 2009-01

Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.

JAMA, 2015-07-07

Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.

Nat Commun, 2019 Mar 27

Diagnosis of fusion genes using targeted RNA sequencing.

Annals of surgery, 2019-04-05

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.

The Lancet. Oncology, 2010-01

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Breast Cancer Res. Treat.,

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-15

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

J. Natl. Cancer Inst.,

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

PLoS ONE, 2018 May 16

The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lancet Oncol., 2015-03-01

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Ann. Surg. Oncol., 2013 Nov 23

Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Lancet Oncol., 2014-06-01

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Breast, 2013 Dec 22

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

Breast, 2015 Oct 09

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Cancer,

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.

J. Clin. Oncol., 2013 Aug 26

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

JAMA, 2014-05-21

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Cancer, 2005-04-15

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

Cancer, 2017-11-01

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Lancet (London, England), 2019-05-04

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Clin. Cancer Res., 2019 Aug 15

Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.

Ann. Oncol.,

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Gastroenterology, 2018 May 17

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

Clin. Gastroenterol. Hepatol., 2018 Nov 28

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.

Hepatology (Baltimore, Md.), 2019-10

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).

Cancer, 2011-11-01

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Case reports in oncology, 2017

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.

BMC Cancer, 2015 Oct 15

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

JAMA oncology, 2019-06-01

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Int J Cancer, 2018 Apr 15

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer.

JAMA Oncol, 2019 Oct 31

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Eur J Surg Oncol, 2014 Oct 07

Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.

Breast cancer research and treatment, 2017-08

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

Ann. Oncol.,

Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)

The Lancet. Oncology, 2018-01

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Annals of surgical oncology, 2018-08

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Lancet Oncol., 2020 Feb 14

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

NCI-CCC Tumor Board Question

Questions discussed in this category

Papers discussed in this category

Related Topics